Evidence map›Paper›PMID 42317268›Full record

ReviewFrontiers in cell and developmental biology2026

Advances in research on RNA methylation and its role in the immune microenvironment of gastrointestinal tumors.

Yushuo Duan, Ziyi Xu, Kaixiang Wen, Chen Xue, Ruile Shen, Xinyu Gu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yushuo DuanDepartment of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Ziyi XuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Kaixiang WenHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Chen XueState Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ruile ShenDepartment of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Xinyu GuHenan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA methylation is a key epigenetic regulatory mechanism that precisely regulates gene expression through the dynamic and reversible actions of "Writers," "Erasers" and "Readers". In recent years, RNA methylation has been widely implicated in tumor formation and immune regulation. For instance, in gastrointestinal tumors, the immunosuppressive state of the tumor microenvironment (TME) is an important factor driving cancer progression. Research indicates that RNA methylation restructures the tumor immune microenvironment (TIME) by modulating tumor and immune cell functions and reprogramming immune metabolism. This process thereby regulates immune evasion and treatment response. Therefore, a better understanding of the mechanism of RNA methylation affecting immune regulation in gastrointestinal tumors can not only help elucidate new patterns of tumor development but also provide important evidence for developing new strategies that combine targeted RNA methylation with immunotherapy. This article aims to review the latest research progress in this field and looks forward to potential clinical applications.

Indexed as

gastrointestinal tumorsimmune evasionimmune prognostic modelRNA methylationtumor immune microenvironment

Identifiers

PMID42317268
PMCPMC13273759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.